A Study to Examine the Safety and Toleration of PEP005 Topical Gel in Patients With Actinic Keratoses on the Top of the Hand

This study has been completed.
Information provided by:
ClinicalTrials.gov Identifier:
First received: October 14, 2007
Last updated: June 6, 2011
Last verified: June 2011

The purpose of this study is to examine the safety and toleration of PEP005 Topical Gel, administered on an actinic keratosis (AK) treatment area on the top of a hand.

Condition Intervention Phase
Actinic Keratosis
Drug: PEP005
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multi-center, Open-label Study to Examine the Safety and Toleration of 0.05% PEP005 Topical Gel in Patients With Actinic Keratoses on the Dorsum of the Hand

Resource links provided by NLM:

Further study details as provided by Peplin:

Primary Outcome Measures:
  • Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs); and Local Skin Responses (LSR) [ Time Frame: 57 days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • The complete clearance rate of AK lesions; partial clearance rate of AK lesions and baseline clearance rate of AK lesions. [ Time Frame: 57 days ] [ Designated as safety issue: No ]

Enrollment: 12
Study Start Date: October 2007
Study Completion Date: January 2008
Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
0.05% PEP005 Topical Gel administered for two consecutive days to a 25cm2 contiguous AK treatment area on the top of the hand
Drug: PEP005
Two day application, 0.05%

Detailed Description:

Actinic keratoses (AK) is a common skin condition characterized by rough, scaly patches or sores on the top layer of the skin which if left untreated can progress to skin cancer. Current treatments can cause scarring and hypopigmentation, be inconvenient, or require long treatment duration. Non-invasive alternative therapy for treatment of AK lesions is thus being researched.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male patients at least 18 years of age.
  • Post-menopausal female patients
  • 4 to 8 clinically typical, visible and discrete AK lesions within an area on the dorsum of one hand.
  • Written informed consent has been obtained.
  • Agreement from the patient to allow photographs of the selected AK treatment area to be taken and used as part of the study data package.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00544297

United States, California
Skin Surgery Medical Group Inc
5222 Balboa Avenue Sixth Floor San Diego, California, United States, 92117
United States, Georgia
Gwinnett Clinical Research Centre
2383 Pate St, Snellville, Georgia, United States, 30078-3250
United States, Texas
Dermatology Associates of Tyler
1367 Dominion Plaza, Tyler, Texas, United States, 75703
Dermatology Clinical Research Centre of San Antonio
7810 Louis Pasteur Dr Suite 200 San Antonio, Texas, United States, 78229-3409
Sponsors and Collaborators
Study Director: Janice Drew Peplin
  More Information

Additional Information:
No publications provided

Responsible Party: Janice Drew, Peplin
ClinicalTrials.gov Identifier: NCT00544297     History of Changes
Other Study ID Numbers: PEP005-018
Study First Received: October 14, 2007
Last Updated: June 6, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Peplin:
Actinic Keratosis

Additional relevant MeSH terms:
Keratosis, Actinic
Precancerous Conditions
Skin Diseases

ClinicalTrials.gov processed this record on March 31, 2015